Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery
Episode
76 min
Read time
3 min
Topics
Productivity, Relationships, Investing
AI-Generated Summary
Key Takeaways
- ✓Hub-and-spoke LLC structure: Nimbus holds assets in separate C-Corps under an LLC parent, allowing pharma partners to acquire single assets without buying the entire platform. This structure enabled a $1.2B Gilead exit for the ACC/NASH program in 2016 and a $4B Takeda deal in 2022, while keeping the core team intact and recycling capital into the next discovery cycle.
- ✓No-lab CRO model for capital efficiency: Nimbus has operated without internal labs for 17 years, relying on CROs for wet-lab execution while keeping a core team of roughly 70. This dial-up/dial-down workforce model, conceived during the 2008 financial crisis, allowed the company to raise only $63M before generating a $600M payout from the Gilead ACC transaction — approximately a 10x return.
- ✓Target selection as primary competitive advantage: Before any chemistry begins, Nimbus evaluates targets across five criteria: structural resolvability, well-understood biology with genetic validation, clinical execution feasibility, competitive landscape, and commercial partnering potential. Programs failing any criterion are killed early. This discipline has produced roughly 75% annual portfolio attrition, recycling over $100M back into early discovery by avoiding late-stage failures.
- ✓Fast-follower strategy with structural differentiation: Nimbus deliberately entered the TYK2 space behind Bristol Myers Squibb, using BMS's clinical progress to refine compound quality. Structural biology work at the atomic level produced 1,500,000-fold selectivity for TYK2 over related JAK family members. Phase 3 data now shows approximately one-third of psoriasis patients achieving complete skin clearance (PASI 100), versus roughly 10-15% for the BMS first-mover compound.
- ✓Kill programs faster to compound discovery output: Kazimi's strategic shift as CEO focuses on accelerating target onboarding and shortening kill decisions rather than protecting programs. The goal is a steady pipeline of clinical-grade assets rather than one blockbuster every several years. Tighter integration of biology, chemistry, and computation — combined with willingness to take on riskier target classes like molecular glues and degraders — defines the next phase of Nimbus's model.
What It Covers
Abbas Kazimi, CEO of Nimbus Therapeutics, describes how a 70-person team with no labs used computational chemistry to discover zazositinib, a TYK2 inhibitor sold to Takeda for $4B upfront in 2022. He outlines the capital-efficient hub-and-spoke LLC model, target selection discipline, and culture that enabled two blockbuster exits across 17 years.
Key Questions Answered
- •Hub-and-spoke LLC structure: Nimbus holds assets in separate C-Corps under an LLC parent, allowing pharma partners to acquire single assets without buying the entire platform. This structure enabled a $1.2B Gilead exit for the ACC/NASH program in 2016 and a $4B Takeda deal in 2022, while keeping the core team intact and recycling capital into the next discovery cycle.
- •No-lab CRO model for capital efficiency: Nimbus has operated without internal labs for 17 years, relying on CROs for wet-lab execution while keeping a core team of roughly 70. This dial-up/dial-down workforce model, conceived during the 2008 financial crisis, allowed the company to raise only $63M before generating a $600M payout from the Gilead ACC transaction — approximately a 10x return.
- •Target selection as primary competitive advantage: Before any chemistry begins, Nimbus evaluates targets across five criteria: structural resolvability, well-understood biology with genetic validation, clinical execution feasibility, competitive landscape, and commercial partnering potential. Programs failing any criterion are killed early. This discipline has produced roughly 75% annual portfolio attrition, recycling over $100M back into early discovery by avoiding late-stage failures.
- •Fast-follower strategy with structural differentiation: Nimbus deliberately entered the TYK2 space behind Bristol Myers Squibb, using BMS's clinical progress to refine compound quality. Structural biology work at the atomic level produced 1,500,000-fold selectivity for TYK2 over related JAK family members. Phase 3 data now shows approximately one-third of psoriasis patients achieving complete skin clearance (PASI 100), versus roughly 10-15% for the BMS first-mover compound.
- •Kill programs faster to compound discovery output: Kazimi's strategic shift as CEO focuses on accelerating target onboarding and shortening kill decisions rather than protecting programs. The goal is a steady pipeline of clinical-grade assets rather than one blockbuster every several years. Tighter integration of biology, chemistry, and computation — combined with willingness to take on riskier target classes like molecular glues and degraders — defines the next phase of Nimbus's model.
- •AI as thinking amplifier, not answer engine: Nimbus treats AI and machine learning as tools to extend the reasoning capacity of its scientists, not as autonomous drug designers. The company beta-tests new computational tools from startups and academic partners on live programs rather than building proprietary platforms. This approach keeps the team asset-light on infrastructure while accessing cutting-edge methods, with the human scientific judgment remaining the core differentiator.
Notable Moment
The morning after announcing the $4B Takeda deal, Kazimi returned to the office expecting celebration and found the team already in their next project meetings. No one was planning an exit. The entire staff had moved on to the next target, which Kazimi describes as the clearest demonstration of what Nimbus's culture actually means in practice.
You just read a 3-minute summary of a 73-minute episode.
Get The Long Run with Luke Timmerman summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from The Long Run with Luke Timmerman
Ep212: Tim Shannon on Creating Targeted Protein Degraders as Medicines
Oct 23 · 74 min
David Senra
Creating Muse: The Fastest-Growing AI Product Since ChatGPT | Alexandr Wang, Meta
Oct 11
More from The Long Run with Luke Timmerman
Ep211: Ardem Patapoutian on Touch, Pain & New Discoveries in Neuroscience
Oct 7 · 66 min
a16z Podcast
The New Startup Playbook | Box CEO Aaron Levie
Oct 25
More from The Long Run with Luke Timmerman
We summarize every new episode. Want them in your inbox?
Ep212: Tim Shannon on Creating Targeted Protein Degraders as Medicines
Ep211: Ardem Patapoutian on Touch, Pain & New Discoveries in Neuroscience
Ep210: Cameron Turtle on Long-Lasting Antibodies for Immune Disorders
Ep209: Mathai Mammen on Developing Drugs Against Undruggable Targets
Ep208: Gary Nabel on Developing a Vaccine for Epstein-Barr Virus
Similar Episodes
Related episodes from other podcasts
David Senra
Oct 11
Creating Muse: The Fastest-Growing AI Product Since ChatGPT | Alexandr Wang, Meta
a16z Podcast
Oct 25
The New Startup Playbook | Box CEO Aaron Levie
The AI Breakdown
Oct 20
Why AI Companies Are Betting Personality Beats Intelligence
WorkLife with Adam Grant
Oct 20
Diagnose your team’s problems with the Waterline Model
a16z Podcast
Oct 16
AI Can Write the Code. Can It Run the System? | Grepr CEO Jad Naous
Explore Related Topics
This podcast is featured in Best Biotech Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Investing & Markets Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into The Long Run with Luke Timmerman.
Every Monday, we deliver AI summaries of the latest episodes from The Long Run with Luke Timmerman and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime